Glucagon-like peptide-1 receptor agonists tied to higher thyroid cancer risk in first year of treatment
The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of treatment, according to a ...
Lexaria begins biodistribution study for DehydraTECH GLP-1
Lexaria Bioscience (LEXX) announces that dosing has begun in its fluorescently tagged DehydraTECH-semaglutide rodent biodistribution study. The ...
Neurology Advisor2d
GLP-1 Receptor Agonists Tied to Risks and Benefits Beyond Weight Loss
For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.
Fast Company12d
GLP-1 drugs like Ozempic may have health benefits, but they come with risks
The Food and Drug Administration’s approval of Ozempic in 2021 for weight loss treatment ushered in a new era for the class ...
thecardiologyadvisor.com3d
No Link Seen Between GLP-1 Receptor Agonist Use and Thyroid Cancer
Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is not associated with an increased risk for thyroid cancer over the short term.
dermatologyadvisor2d
GLP-1 RAs Tied to Higher Thyroid Cancer Risk in First Year of Treatment
The absolute risk for thyroid cancer is low among patients receiving GLP-1 RA therapy, but risk is elevated in the first year of treatment.
AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS
Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2024 versus comparable periods in 2023.
C&EN8d
Weight-loss start-up emerges from stealth
The soaring demand for antidiabetic and weight-loss drugs has lured in many biotech and big Pharma companies. Onto this ...
Amgen says Phase 1 AMG 513 obesity study placed on clinical hold by FDA
Amgen (AMGN) provided updates on selected product and pipeline programs, including that a Phase 1 study of AMG 513 in people living with ...
Lexaria Biodistribution Study For DehydraTECH GLP-1 is Underway
Ever Study Tracking Biodistribution of DehydraTECH GLP-1 Molecules KELOWNA, BC / ACCESS Newswire / February 6, 2025 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), ...
Lexaria Bioscience Corp.: Lexaria Biodistribution Study For DehydraTECH GLP-1 is Underway
World's First-Ever Study Tracking Biodistribution of DehydraTECH GLP-1 Molecules KELOWNA, BC / ACCESS Newswire / February 6, 2025 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" ...